Scientists at Taipei Medical University in Taiwan have developed a compound that could prevent resistance to temozolomide in the chemical treatment of glioblastoma.
Shanghai Allist Pharmaceuticals Co. Ltd. has patented nitrogen-containing heterocyclic compounds acting as GTPase KRAS, particularly G12D or G12V mutant, inhibitors reported to be useful for the treatment of cancer.
Abbvie Inc. has prepared and tested new antibody-drug conjugates comprising an antibody targeting seizure protein 6 homolog (SEZ6) covalently linked to DNA topoisomerase I inhibitors through a linker.
Asgard Therapeutics AB has raised €30 million (US$32.8 million) in a series A round to advance a novel approach to cancer immunotherapy, in which it is proposed to reprogram cancer cells into functional antigen-presenting dendritic cells in vivo, activating a host immune response against the tumor.
Hangzhou Highlightll Pharmaceutical Co. Ltd. has identified NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, inflammation, liver and metabolic disease, neuroinflammation, immunological, cardiovascular and renal disorders.
Preclinical data were recently presented for VIO-01 (Valerio Therapeutics SA), a first-in-class pan-DNA damage response (DDR) decoy being developed for the treatment of cancer.
The H. Lee Moffitt Cancer Center and Research Institute has described cyclin-dependent kinase (CDK) inhibitors reported to be useful for the treatment of cancer, inflammation and myotonic dystrophy type 1 disease.
RSS
